(Q46968784)

27 December 2017

title

Pharmacokinetic profile of temsirolimus with concomitant administration of cytochrome p450-inducing medications (English)

1 reference

27 December 2017

1 reference

Joseph Boni

1

1 reference

27 December 2017

Cathie Leister

2

1 reference

27 December 2017

Jaime Burns

3

1 reference

27 December 2017

Maria Cincotta

4

1 reference

27 December 2017

Bruce Hug

5

1 reference

27 December 2017

Laurence Moore

6

1 reference

27 December 2017

publication date

3 October 2007

1 reference

27 December 2017

The Journal of Clinical Pharmacology

published in

1 reference

27 December 2017

volume

47

1 reference

27 December 2017

issue

11

1 reference

27 December 2017

page(s)

1430-1439

1 reference

27 December 2017

Substrates of human hepatic cytochrome P450 3A4.

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270007306957

CYP3A4 induction by xenobiotics: biochemistry, experimental methods and impact on drug discovery and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007306957

Rifampicin, a keystone inducer of drug metabolism: from Herbert Remmer's pioneering ideas to modern concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007306957

Pharmacokinetic interactions with rifampicin : clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007306957

The TOR pathway: a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007306957

Current development of mTOR inhibitors as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007306957

Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007306957

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007306957

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007306957

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007306957

Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007306957

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007306957

The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007306957

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007306957

Population pharmacokinetics of CCI-779: correlations to safety and pharmacogenomic responses in patients with advanced renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007306957

Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007306957

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007306957

Increase in tacrolimus trough levels after steroid withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007306957

Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007306957

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007306957

Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007306957

21 January 2018

Identifiers

DOI

10.1177/0091270007306957

1 reference

27 December 2017

1 reference

27 December 2017